Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Suicidality

MDMA for Suicidality

16 papers and 0 clinical trials exploring mdma as a treatment for suicidality.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
Indication700,000 deaths annually worldwide.

Suicidality

Suicidality encompasses a spectrum of suicidal thoughts and behaviours, significantly impacting individuals globally. Recent research into psychedelics, particularly ketamine and ayahuasca, shows promise in rapidly alleviating suicidal ideation associated with mental health disorders.

Full Suicidality profile

Academic Research

16 papers
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.
Paywallindividual

MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial

This long-term follow-up (n=12) of participants with moderate-to-severe major depressive disorder who received MDMA-assisted therapy (two dosing sessions integrated with nine psychotherapy sessions) found significant reductions in depression severity and functional impairment at seven months compared to baseline, with improvements maintained from the post-treatment assessment and no increases in suicidal ideation.

Published
February 1, 2026
Journal
Journal of Psychiatric Research
Authors
Kvam, T. M., Goksøyr, I. W., Rog, J., van de Vooren, I. T. J., Stewart, L. H., Autran, I., Berthold-Losleben, M., Mørch-Johnsen, L., Holst, R., Røssberg, J. I., Clausen, I., Andreassen, O. A.
Open Accessmeta

The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD

This paper articulates the conceptual framework behind the inner‑directed, relational and trauma‑informed psychotherapeutic approach used in Phase 3 MDMA‑assisted therapy trials for PTSD, centring the participant’s "inner healing intelligence", a non‑pathologising stance, therapist attunement, and integration of top‑down and bottom‑up processes. It notes that MDMA plus therapy outperformed placebo plus therapy on symptom reduction, while substantial improvement in control groups underscores the psychotherapy model’s independent efficacy and the need to identify which elements drive clinical benefit.

Published
November 4, 2024
Journal
Frontiers in Psychology
Authors
O'Donnell, K., Okano, L., Alpert, M., Nicholas, C. R., Thomas, C., Poulter, B., Mithoefer, A. T., Mithoefer, M. C., Ot’alora G, M.
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Paywallmeta

MDMA-Assisted Psychotherapy for Borderline Personality Disorder

This review (2022) makes the cases for using MDMA-assisted therapy (MDMA-AT) in the treatment of borderline personality disorder (BPD). The authors draw parallels between using MDMA-AT to treat disorders similar to BPD, such as PTSD, and provide considerations for designing future clinical trials.

Published
October 25, 2022
Journal
Focus
Authors
Traynor, J. M., Roberts, D. E., Ross, S., Zeifman, R., Choi-Kain, L.
Open Accessindividual

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

The paper proposes that MDMA facilitates extinction of traumatic memories in PTSD by increasing BDNF availability in fear‑memory circuits, thereby enhancing synaptic plasticity for relearning and extinction. It argues this molecular action, together with MDMA’s pro‑social effects that strengthen the therapeutic alliance, explains the clinical benefits of MDMA‑assisted therapy.

Published
October 12, 2022
Journal
Frontiers in Psychiatry
Authors
Sottile, R. J., Vida, T.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Suicidality yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Suicidality trials Full MDMA profile Full Suicidality profile